Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
Drug common name | Dexpramipexole |
INN | dexpramipexole |
Description | Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCN[C@@H]1CCc2nc(N)sc2C1 |
PDB | — |
CAS-ID | 104617-86-9 |
RxCUI | — |
ChEMBL ID | CHEMBL249420 |
ChEBI ID | — |
PubChem CID | 59868 |
DrugBank | — |
UNII ID | WI638GUS96 (ChemIDplus, GSRS) |